GlassScriptPhysician profile
Lissa Mcclendon
NPI 1194425298
$3,416.00
in general payments reported to CMS, 2019-2025
28 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what 93% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,043 · 2024: $959 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,341 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,341.01 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $419.03 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $383.03 | 2023-2025 | Lynparza |
| Glaxosmithkline, LLC. | $357.91 | 2023-2024 | Jemperli, Zejula |
| Genmab U.S., INC. | $351.98 | 2023-2025 | Tivdak |
| Merck Sharp & Dohme LLC | $296.10 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $291.00 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Integra Lifesciences Corporation | $175.03 | 2025 | Codman Certas, Codman Hakim, Cusa Clarity |
| Abbvie INC. | $147.45 | 2023-2025 | |
| Immunogen, INC. | $145.17 | 2023 | Elahere |
| Seagen INC. | $139.99 | 2023-2025 | Tivdak |
| Tempus Ai, INC | $125.06 | 2024 | |
| Spectrum Pharmaceuticals INC. | $88.62 | 2024-2025 | Rolvedon |
| Novartis Pharmaceuticals Corporation | $83.71 | 2023-2024 | |
| Foundation Medicine, INC. | $74.22 | 2023 | |
| Stemline Therapeutics INC. | $40.74 | 2023 | Orserdu |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.38 | 2023-2024 | Veozah |
| Janssen Biotech, INC. | $38.05 | 2023-2024 | Rybrevant, Imbruvica, Darzalex |
| Takeda Pharmaceuticals U.S.A., INC. | $27.95 | 2024 | Alunbrig |
| Progenics Pharmaceuticals, INC. | $24.43 | 2024 | |
| Ethicon US, LLC | $20.82 | 2025 | Enseal |
| Immunocore Limited | $20.73 | 2024 | Kimmtrak |
| Genentech USA, INC. | $20.15 | 2024 | Lunsumio, Polivy |
| Emd Serono, INC. | $18.90 | 2023 | Tepmetko |
| Pfizer INC. | $18.83 | 2024 | |
| Caris Mpi, INC. | $17.22 | 2025 | Mi Cancer Seek |
| Taiho Oncology, INC. | $17.05 | 2024 | |
| Baxter Healthcare | $16.69 | 2025 | Perclot |
| Pharmaand Gmbh | $15.76 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lissa Mcclendon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.